CanaQuest Press Release of a Research Report on CanaQuest by Fundamental Research Corp.

Published: March 24, 2021

CanaQuest Press Release of a Research Report on CanaQuest by Fundamental Research Corp.

CANAQUEST MEDICAL CORP., a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that Fundamental Research Corp (“FRC”), one of the world’s largest independent research houses, has launched coverage on CanaQuest with a BUY Rating. Its full report is available here: https://canaquest.com/wp-content/uploads/2021/03/CanaQuest-Research-Report-by-FRC-March-2021.pdf

FRC has a 17-year track record of covering 550+ companies since inception. An excerpt from FRC’s report is included below…

“In conclusion, we believe the company’s formulations have potential to generate demand based on their differentiating features. Even though we are not in position to verify the company’s claims regarding higher efficacy levels, we believe recognition by academic journals is highly encouraging. The company’s prospects are heavily dependent on management’s ability to raise capital and obtain approvals. We believe the current financing (if completed), and near-term sales of non-Rx products will be the key catalysts this year. We are initiating coverage with a BUY rating, and a fair value estimate to US$0.78.“

Fundamental Research Corp is one of the largest independent research houses in the world, with a 17-year track record of covering 550+ companies. As of March 12, 2021, FRC’s top picks were up 76.4% on average since initiation of coverage. The Company is a premier research firm that has ranked in the Top Ten in independent third-party evaluations of its research. For more information on Fundamental Research Corp, visit www.researchfrc.com

CanaQuest Medical Corp is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade). The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, who has 20 years of research experience in the field of mental health and cannabinoids and oversees a team of 13 scientists at Western University. The Company’s research is focused on the use of cannabinoids for the development of novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest has identified the regulatory pathways to obtain Drug Identification Numbers (DINs) for its two Master Formations, Mentanine®Rx and Mentabinol®Rx in Canada and the USA.

Recent News

View All News Items

Latest Article

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

At any step in the cannabis supply chain, your labeling system should allow for full control and traceability, from seed to sale. Implementing lean principles and labeling best practices across the cannabis supply chain can help you streamline your seed-to-sale labeling process and help you gain control.

Click below to read the full blog and learn how to reduce waste, cut costs, and gain efficiency with cannabis labeling: https://bit.ly/2KwZ5IQ

Read Article